Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

被引:947
作者
Clavien, Pierre-Alain [1 ]
Lesurtel, Mickael [1 ]
Bossuyt, Patrick M. M. [2 ]
Gores, Gregory J. [3 ]
Langer, Bernard [4 ]
Perrier, Arnaud [5 ]
机构
[1] Univ Zurich Hosp, Dept Surg, Swiss HPB & Transplant Ctr, CH-8091 Zurich, Switzerland
[2] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[3] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
[4] Univ Toronto, Dept Surg, Toronto, ON, Canada
[5] Univ Hosp Geneva, Dept Internal Med, Geneva, Switzerland
关键词
SIROLIMUS-BASED IMMUNOSUPPRESSION; GAMMA-CARBOXY PROTHROMBIN; TOTAL TUMOR VOLUME; LIVING DONOR; MICROVASCULAR INVASION; ADJUVANT CHEMOTHERAPY; SELECTION CRITERIA; STAGING-SYSTEM; NONCIRRHOTIC LIVER; CIRRHOTIC-PATIENTS;
D O I
10.1016/S1470-2045(11)70175-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Although liver transplantation is a widely accepted treatment for hepatocellular carcinoma (HCC), much controversy remains and there is no generally accepted set of guidelines. An international consensus conference was held on Dec 2-4, 2010, in Zurich, Switzerland, with the aim of reviewing current practice regarding liver transplantation in patients with HCC and to develop internationally accepted statements and guidelines. The format of the conference was based on the Danish model. 19 working groups of experts prepared evidence-based reviews according to the Oxford classification, and drafted recommendations answering 19 specific questions. An independent jury of nine members was appointed to review these submissions and make final recommendations, after debates with the experts and audience at the conference. This report presents the final 37 statements and recommendations, covering assessment of candidates for liver transplantation, criteria for listing in cirrhotic and non-cirrhotic patients, role of tumour downstaging, management of patients on the waiting list, role of living donation, and post-transplant management.
引用
收藏
页码:E11 / E22
页数:12
相关论文
共 105 条
[1]
Australia and New Zeland Liver Transplant Registry, 21 AUSTR NZ LIV TRAN
[2]
Underlying liver disease, not tumor factors, predicts long-term survival alter resection of hepatocellular carcinoma [J].
Bilimoria, MM ;
Lauwers, GY ;
Doherty, DA ;
Nagorncy, DM ;
Belghiti, J ;
Do, KA ;
Regimbeau, JM ;
Ellis, LM ;
Curley, SA ;
Ikai, I ;
Yamaoka, Y ;
Vauthey, JN .
ARCHIVES OF SURGERY, 2001, 136 (05) :528-534
[3]
Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[4]
Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[5]
Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver [J].
Chang, CH ;
Chau, GY ;
Lui, WY ;
Tsay, SH ;
King, KL ;
Wu, CW .
ARCHIVES OF SURGERY, 2004, 139 (03) :320-325
[6]
Chen Gui-Hua, 2004, Zhonghua Wai Ke Za Zhi, V42, P1040
[7]
CHERQUI D, 1994, CANCER, V73, P2721, DOI 10.1002/1097-0142(19940601)73:11<2721::AID-CNCR2820731112>3.0.CO
[8]
2-K
[9]
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma [J].
Chevret, S ;
Trinchet, JC ;
Mathieu, D ;
Rached, AA ;
Beaugrand, M ;
Chastang, C .
JOURNAL OF HEPATOLOGY, 1999, 31 (01) :133-141
[10]
Impact of Sirolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation [J].
Chinnakotla, Srinath ;
Davis, Gary L. ;
Vasani, Sugam ;
Kim, Peter ;
Tomiyama, Koji ;
Sanchez, Edmund ;
Onaca, Nicholas ;
Goldstein, Robert ;
Levy, Marlon ;
Klintmalm, Goeran B. .
LIVER TRANSPLANTATION, 2009, 15 (12) :1834-1842